Can Mira help during menopause or while adjusting HRT?Updated 2 months ago

Mira can help perimenopausal users observe cycle irregularity, anovulation, and hormone fluctuations. Mira provides quantitative data that can help clarify whether HRT is supporting more coordinated hormone activity. Mira data can also help validate symptoms and guide treatment discussions. 

In postmenopausal individuals, estrogen and progesterone levels are typically low and relatively stable, while FSH often remains elevated and variable. Although routine cycle tracking has limited utility after menopause, FSH remains a clinically meaningful biomarker, as persistently elevated FSH has been associated with multiple long-term health risks.

For patients using hormone replacement therapy (HRT), FSH tracking provides an important way to assess treatment effectiveness. While Mira E3G values alone are not sufficient to determine whether estrogen therapy is therapeutic, serial FSH monitoring—interpreted alongside E3G trends and patient-reported symptom response—can indicate whether estrogen is being absorbed and exerting appropriate physiologic feedback.

Mira is most clinically useful when these measures are evaluated together. Suppression or stabilization of FSH over time, combined with symptom improvement, offers a practical approach to evaluating HRT response and potential risk reduction—insight that serum E2 or urinary E3G values alone cannot provide. This makes ongoing Mira monitoring a valuable tool in both perimenopause and postmenopause.